Key Takeaways
- Earnings reset masks steady-state rebuild: Revenue fell to INR 513.3 cr (vs INR 590.7 cr YoY) and net profit to INR 62.3 cr (vs INR 80.4 cr) solely because the prior-year quarter included a one-time licensing fee; the underlying business has been rebuilt to replace vanished blockbusters like Oseltamivir.
- Agro entry is the quarter's big bet: CTPR launched all combinations with a INR 150–200 cr revenue target over the next 12 months at 20–25% net margins, making it the anchor of a new INR 400–500 cr long-term business.
- Revlimid profit share is back-loaded into Q4 and Q1: Very little booked in Q3, but volume share is expected to move from mid-single-digit to double digits from March 7, with a significant profit increase; management declined to discuss pricing or litigation risk.
- Domestic business is a declared 5–7 year fix: Now ~15–16% of revenue and declining, management aims to grow it to 30–35% via portfolio expansion, field force build-out, and M&A, but warns patience is required.
- What to watch next quarter: Revlimid profit share magnitude in Q4, CTPR agro revenue traction in the January–March season, and whether a domestic M&A deal is consummated in 2023.
Agro Division: The New Growth Engine
- CTPR launch is the anchor: All combinations launched across pack sizes from 10 ml to 150 ml, with 300 ml and 600 ml packs on the way; management calls it the most important product in a 5–6 year pipeline.
- Revenue ambition: INR 150–200 cr in the next 12 months, with Q1 (kharif) the biggest quarter; 5–6 B2B customers already onboarded, expected to contribute 25–30% of sales, with own-label at 65–70%.
- Margins and competitive moat: Net margin expected at 20–25% after all expenses; patents valid till 2025 and litigation wins limit suppliers to 2–3, so B2B does not destroy pricing.
- Infrastructure built over two years: Sales force, manufacturing capability, and distribution are in place; Karnataka team onboarding now, full coverage expected in 1–2 months across all states including Maharashtra, Madhya Pradesh, and the South.
- Long-term path: Can grow to INR 400–500 cr, mostly branded India business initially, with exports eventually picking up; a steady pipeline of products is lined up for the next 5–6 years.
Rajeev Nannapaneni: "When we enter a market we don't try to be the -- we always like the only show in town or the only 1 or 2 shows in town so that your chances of success are much higher compared to a..."
Revlimid: The Known Unknown
- Profit share timing: Very little Revlimid revenue booked in Q3; profit share will be recognised in Q4 FY23 and Q1 FY24, with quantity for Q1 already shipped.
- Volume share inflection: Expected to move from mid-single-digit to double digits from March 7 onwards, driving a significant profit increase.
- Pricing and competition questions deflected: Management declined to discuss current industry pricing, whether market-share gains would be offset by price declines from incremental competition, and the litigation case's potential adverse outcomes, stating only that it is confident in its position.
- Steady-state context: Even without one-time licensing fees, steady-state revenue today equals what the company made about 3, 4 years ago when it had all the one-times.
Base Business Transformation
- The old earnings model is gone: Oseltamivir has completely vanished, Doxorubicin is down 85–90%, and 40–50% of earnings used to come from big one-time products; the company rebuilt through subsidiaries in Brazil and Canada, ROW business, and the agro division.
- Subsidiaries now drive nearly 40% of PAT: Subsidiary revenue was INR 169 cr this quarter; Brazil has 5–6 launches in the next 12 months, Canada has good launches coming in the next few months, and the diversified portfolio is designed to protect against single-product price drops.
- US strategy is deliberately contrarian: The company makes money in the US when others do not by avoiding commodities and focusing on niche, hard-to-do generics; 11 of ~26 commercial US products are approved Para IVs, generally higher value due to limited competition.
- Margins reflect the new reality: Building a sustainable wider business across multiple geographies without supernormal profit leads to lower margins; management says there is no way around it.
Rajeev Nannapaneni: "I'm exactly doing the opposite of what the industry is doing. So we are making money in US, when nobody is making money in the US and people are making money in India, we're not making as much money as in India."
Domestic Business: The Long Fix
- Current state is weak: Domestic business is ~15–16% of top line, growth is missing, and the business has been declining; historically the company only did a niche segment and now faces heavy oncology competition.
- Portfolio and field force expansion underway: New divisions covering GPs, cardio, and diabeto have been launched, and the field force is being expanded; benefits are expected in the next few years.
- M&A is part of the plan: The company is looking for an acquisition to get better reach and a deeper portfolio; it missed an asset in 2022 but is hopeful of consummating a deal in 2023, with a focus on higher margin, low field force, and fair return on capital.
- Target is 30–35% of top line: Management wants to grow domestic share to levels consistent with larger peers, but warns this is a 5–7 year transformation cycle.
Rajeev Nannapaneni: "Doing no deal is better than doing a bad deal, right? So I think we'll find something. I'm confident. You have to be patient. You have to wait. Sometimes -- see, I am not under pressure in that sense, right, because we have steady earnings"
Earnings Pattern & Lumpiness
- Q4 and Q1 will remain the strong halves: Revlimid profit share and agro sales (kharif and some rabi) concentrate in Q4 and Q1, with Q1 the biggest agro quarter; Q2 and Q3 are structurally slower, and this lumpy pattern is expected to continue for the next few years.
- Full-year FY23 guidance: Top line of INR 2,700–2,800 cr and PAT closer to INR 700 cr, which would be the highest revenue and highest PAT in company history.
- Management looks at earnings annually: Given the lumpiness, the company evaluates performance on a full-year basis rather than quarter-to-quarter.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Agro revenue | INR 150–200 cr | Next 12 months |
| Agro net margin | 20–25% after all expenses | Ongoing |
| Full-year FY23 top line | INR 2,700–2,800 cr | FY23 |
| Full-year FY23 PAT | Closer to INR 700 cr | FY23 |
| Revlimid volume share | Move from mid-single-digit to double digits | From March 7 onwards |
| Revlimid profit share booking | Recognised in Q4 FY23 and Q1 FY24 | Q4 FY23, Q1 FY24 |
| Brazil subsidiary launches | 5–6 launches | Next 12 months |
| Domestic M&A deal | Hopeful of consummating a deal | 2023 |
| Domestic business share target | Grow to 30–35% of top line | 5–7 year cycle |
| Agro business long-term scale | Grow to INR 400–500 cr | No fixed date; exports eventually |
| Karnataka agro sales team | Full team in place | Next 1–2 months |
| US new filings FTF clarity | Clarity on first-to-file status | Next 2–3 months |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Consolidated total revenue | ₹513.3 cr, versus ₹590.7 cr in Q3 FY22 which included a one-time licensing fee |
| Consolidated net profit | ₹62.3 cr, versus ₹80.4 cr in Q3 FY22 |
| Full-year FY23 revenue guidance | ₹2,700 cr to ₹2,800 cr, expected highest in company history |
| Full-year FY23 PAT guidance | Closer to ₹700 cr, expected highest in company history |
| Agro division revenue | Less than ₹10 cr, initial quarter post-launch |
| Agro division revenue expectation (next 12 months) | ₹150 cr to ₹200 cr |
| Agro division long-term revenue expectation | ₹400 cr to ₹500 cr, mostly branded India business with eventual export pickup |
| Agro division expected net margin | 20% to 25%, broadly ₹25 to ₹30 on ₹100 after all expenses |
| Domestic formulation revenue | ~₹400 cr, approximately 15% to 16% of top line |
| Cash on books | ₹1,030 cr, with very little debt except working capital debt |
| Subsidiary revenue | ₹169 cr for the quarter |
| Subsidiary PAT contribution | Nearly 40% of consolidated PAT |
| US commercial products | ~26 commercial products, of which 11 are Para IV approved |
| Para IV pipeline | 19 Para IV filings in pipeline as of March 31, 2022 |
| CTPR market size | ~₹3,000 cr |